Avoiding Buyer's Remorse

Where have all the buyers gone? While biopharma and medtech have seen some increased M&A activity in 2024, healthcare services buyers have been more timid. And 1 in 3 healthcare exits are now falling short of their last private valuation. So, if you're a founder, is it time to polish up that pitch deck and start courting potential buyers or is leaving the private nest a little too risky? How many acquirers truly understand the complexities of scaling a healthcare business anyway? Well, not so fast. The market is evolving, and both strategic and financial buyers are becoming increasingly sophisticated in their evaluation processes. PE firms and investors have a sharper focus on operational value-add and realistic growth projections. In response, startups should demonstrate sustainable growth and real-world impact. And for the rest of us? Knowledge is power so tune in to the dealmakers to learn the do's and don'ts of navigating healthcare exits in this challenging environment.